Drug Profile
AVN 944
Alternative Names: AVN944; VX 944Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Avalon Pharmaceuticals; Clinical Data; Vertex Pharmaceuticals
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Haematological malignancies; Pancreatic cancer
Most Recent Events
- 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
- 11 Mar 2010 Discontinued - Phase-I for Haematological malignancies in USA (PO)
- 29 May 2009 Avalon Pharmaceuticals has been acquired and merged into Clinical Data